Movinavir is made in the form of hard capsules, with the main active ingredient being Molnupiravir. The drug is used in the treatment of mild and moderate COVID-19 in adults with the disease, who are at risk of worsening the disease.

Convalescent plasma therapy in the treatment of COVID-19 patients is considered and evaluated as a potential new therapy to increase the tools for doctors to treat patients, especially those with severe disease progression.